Notícias e Atividades da Madrigal Pharmaceuticals

Madrigal Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Madrigal Pharmaceuticals é uma empresa listada sob o símbolo MDGL (US).

Veja o organograma con seus 32 executivos principais

Biografias mais buscadas da Madrigal Pharmaceuticals

• Bill Sibold, Chief Executive Officer and Director
• Paul Friedman, Director
• Fred Craves, Lead Director

Recentes movimentos de executivos em Madrigal Pharmaceuticals

• Beata Czajkowska, ingressou na Companhia como Senior Director, Talent Access International  (Notícia publicada em 5 de maio de 2025).
• David Soergel, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 16 de abril de 2025).
• Jacqualyn Fouse, ingressou na Companhia como Director  (Notícia publicada em 13 de março de 2025).

Clique aqui para ver outras movimentos em Madrigal Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals possui 1.838 concorrentes concorrentes Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) e Sanofi (França).

Popular M&A news in Farmacêutica

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado em 16 de junho de 2025).
• Juvenescence acaba de anunciar uma arrecadação de fundos de 76 milhões de dólares. (publicado em 22 de maio de 2025).
• Kincell Bio acaba de anunciar uma arrecadação de fundos de 22 milhões de dólares. (publicado em 22 de maio de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations da Abeona Therapeutics
• Keiichi Ando - Independent Non-Executive Director da Shionogi

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Madrigal Pharmaceuticals

• Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 | Madrigal Pharmaceuticals.
• Press Releases | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) | Madrigal Pharmaceuticals.
• Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | Madrigal Pharmaceuticals.
• View more press releases Close

Redes sociais sobre Madrigal Pharmaceuticals

• Madrigal Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Madrigal Pharmaceuticals na LinkedIn, Twitter e YouTube